tralokinumab

This page shows the latest tralokinumab news and features for those working in and with pharma, biotech and healthcare.

AZ gets EMA green light for severe asthma drug Fasenra

Prospects for IL-13 inhibitor tralokinumab look terminal after three failed late-stage trials, however, and AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase

Latest news

AZ prices severe asthma drug Fasenra below competition

Prospects for IL-13 inhibitor tralokinumab look rocky after two failed late-stage trials, elevating the importance of Fasenra in those plans.
AZ severe asthma drug benralizumab backed by CHMP

Benralizumab has assumed much greater importance for the company since IL-13 inhibitor tralokinumab - another severe asthma candidate - failed two phase III trials.
Setback for AZ as tralokinumab flunks asthma trial

Setback for AZ as tralokinumab flunks asthma trial. Puts more pressure on AZ’s benralizumab to reach its potential. ... Tralokinumab is an inhibitor of interleukin-13 (IL-13), while benralizumab works by blocking the activity of IL-5.
Roche out-licenses lebrikizumab rights to Dermira

Disappointing results with other IL-13-targeting drugs in asthma - including Pfizer's anrukinzumab and AstraZeneca's tralokinumab - undermined confidence in the approach.
AZ trial adds to pessimism about anti-IL-13 asthma drugs

Prospects for drugs targeting interleukin-13 for asthma treatment have taken another knock after AstraZeneca's tralokinumab failed a phase III trial. ... It looks increasingly like a lost cause as AZ already reported disappointing phase IIb data with

More from news
Approximately 4 fully matching, plus 15 partially matching documents found.

Latest Intelligence

2016: The year when deal-makers took stock?

Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business.
Deal Watch July 2016

AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis. ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13)

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Medical Writer, e-learning/ training, London: Excellent Salary

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Medical Writer: Great salary and bebefits

Editorial Director – Medical Education – Oxford: Negotiable

Medical Writer - (London, Brighton or Copenhagen): Competitive

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Scientific Director: Great salary and bebefits

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Account Manager – Med Comms – London: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Project Manager, Medical Communications, Oxford: Excellent Salary

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Project Manager, Medical Communications, London: Excellent Salary

Senior Medical Writer: Great salary and benefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Subscribe to our email news alerts

PMHub

Add my company

Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...